ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.3122C>G (p.Ser1041Ter)

dbSNP: rs397509035
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000256646 SCV000323566 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2016-10-18 reviewed by expert panel curation Variant allele predicted to encode a truncated non-functional protein.
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge RCV000256646 SCV000325562 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2015-10-02 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000256646 SCV000915765 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2017-09-12 criteria provided, single submitter clinical testing The BRCA1 c.3122C>G (p.Ser1041Ter) variant is a stop-gained variant that has been reported in two studies and detected in four individuals with breast or ovarian cancer (Li et al. 2008; Kim et al. 2016). Li et al. (2008) report one individual with breast cancer and a family history of the disease and Kim et al. (2016) report three more individuals with breast or ovarian cancer. All the affected individuals are from mainland China. Control data are unavailable for the p.Ser1041Ter variant and frequency information is not available from the 1000 Genomes Project, the Exome Sequencing Project, the Exome Aggregation Consortium or the Genome Aggregation Database. The p.Ser1041Ter variant is predicted to truncate 44% of the BRCA1 protein, and Ser1041 is predicted to be a phosphorylation site (Savas et al. 2005). Based on the evidence and the potential impact of stop-gained variants, the p.Ser1041Ter is classified as pathogenic for hereditary breast and ovarian cancer. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Labcorp Genetics (formerly Invitae), Labcorp RCV002513657 SCV003441964 pathogenic Hereditary breast ovarian cancer syndrome 2022-01-02 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 54773). This variant is also known as 3241C>G. This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 17851763, 17922413). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ser1041*) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584).
Laboratory for Genotyping Development, RIKEN RCV003162405 SCV002758206 pathogenic Gastric cancer 2021-07-01 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.